(icTV) Commentary on the HYPRESS Trial

Commentary on the HYPRESS Trial 

icTV Interview with Todd Dorman

SCCM President Todd Dorman comments on the HYPRESS trial on the use of hydrocortisone for the prevention of septic shock. He highlights the strengths and limitations of this randomised controlled trial and notes several key considerations for future studies. 

The results of this clinical trial were originally presented October 3rd during the President's Session at LIVES 2016 in Milan and simultaneously published in JAMA.

Link to the article in JAMA here.

<Back to the news list
Comment on this news Comment on this news
To respond to this article, thank you for identifying
ReactionsReactions (0)